MA39146A1 - Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma - Google Patents

Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma

Info

Publication number
MA39146A1
MA39146A1 MA39146A MA39146A MA39146A1 MA 39146 A1 MA39146 A1 MA 39146A1 MA 39146 A MA39146 A MA 39146A MA 39146 A MA39146 A MA 39146A MA 39146 A1 MA39146 A1 MA 39146A1
Authority
MA
Morocco
Prior art keywords
gabapentanoids
combinations
receptor ligands
sigma receptor
combination
Prior art date
Application number
MA39146A
Other languages
English (en)
French (fr)
Inventor
Daniel Zamanillo-Castanedo
Enrique Portillo-Salido
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49876521&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA39146(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of MA39146A1 publication Critical patent/MA39146A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA39146A 2013-12-17 2014-12-16 Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma MA39146A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13382517 2013-12-17
PCT/EP2014/077992 WO2015091505A1 (en) 2013-12-17 2014-12-16 Gabapentinoids and sigma receptor ligands combinations

Publications (1)

Publication Number Publication Date
MA39146A1 true MA39146A1 (fr) 2017-11-30

Family

ID=49876521

Family Applications (1)

Application Number Title Priority Date Filing Date
MA39146A MA39146A1 (fr) 2013-12-17 2014-12-16 Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma

Country Status (16)

Country Link
US (1) US20160310501A1 (enExample)
EP (1) EP3082790A1 (enExample)
JP (1) JP2017503765A (enExample)
KR (1) KR20160098426A (enExample)
CN (1) CN105873580B (enExample)
AR (1) AR101637A1 (enExample)
AU (1) AU2014364644A1 (enExample)
CA (1) CA2933057A1 (enExample)
IL (1) IL245977A0 (enExample)
MA (1) MA39146A1 (enExample)
MX (1) MX2016007286A (enExample)
PH (1) PH12016501095A1 (enExample)
SG (1) SG11201604478UA (enExample)
TN (1) TN2016000229A1 (enExample)
TW (1) TW201607539A (enExample)
WO (1) WO2015091505A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
TW201607538A (zh) 2013-12-17 2016-03-01 以斯提夫博士實驗室股份有限公司 血清素－去甲腎上腺素再攝取抑制劑（ＳＮＲＩＳ）和σ受體配體組合物
EP3727338A1 (en) * 2017-12-19 2020-10-28 University of Tennessee Research Foundation W/o/w microemulsions for ocular administration
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN120437109B (zh) * 2025-07-09 2025-09-26 湖南一格制药有限公司 一种稳定性优异的苯磺酸美洛加巴林制剂组合物

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2460891C2 (de) 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
WO1992009560A1 (en) 1990-11-27 1992-06-11 Northwestern University Gaba and l-glutamic acid analogs for antiseizure treatment
AU677008B2 (en) 1992-05-20 1997-04-10 Northwestern University Gaba and L-glutamic acid analogs for antiseizure treatment
ES2260850T3 (es) 1997-10-27 2006-11-01 Warner-Lambert Company Llc Aminoaciods ciclicos y sus derivados utiles como agentes farmaceuticos.
JP2002508362A (ja) 1997-12-16 2002-03-19 ワーナー−ランバート・カンパニー １−置換−１−アミノメチル−シクロアルカン誘導体（＝ガバペンチン類縁体）、その製造および神経学的疾患の治療におけるその使用
HUP0100069A3 (en) 1997-12-16 2002-04-29 Warner Lambert Co 4(3)substituted-4(3)-aminomethyl-pyran, or -thiopyran-piperidine derivatives, their preparation and their use in the treatment of neurological disorders
PL348305A1 (en) 1997-12-16 2002-05-20 Warner Lambert Co Novel amines as pharmaceutical agents
KR20010043831A (ko) 1998-05-26 2001-05-25 로즈 암스트롱, 크리스틴 에이. 트러트웨인 칼슘 채널의 알파2델타 서브유닛에 대한 친화력이 있는구조적으로 한정된 아미노산 화합물
US6166072A (en) 1998-08-03 2000-12-26 Allelix Neuroscience, Inc. Amino acid derivatives
AU1602100A (en) 1998-11-25 2000-06-13 Warner-Lambert Company Improved gamma amino butyric acid analogs
CA2359485A1 (en) * 1999-03-10 2000-09-14 Warner-Lambert Company Analgesic compositions comprising anti-epileptic compounds and methods of using same
DE60012508T2 (de) 1999-05-26 2005-06-23 Warner-Lambert Company Llc Aminosäuren mit polycyclischer struktur als pharmaka
TR200103399T2 (tr) 1999-05-28 2002-04-22 Warner-Lambert Company 3-heteroarilalkil ikameli GABA analogları.
WO2000073300A1 (en) 1999-06-02 2000-12-07 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
NZ528151A (en) 2001-04-19 2005-04-29 Warner Lambert Co Fused bicyclic or tricyclic amino acids
US7696199B2 (en) 2004-08-27 2010-04-13 Laboratorios Del Dr. Esteve, S.A. Sigma receptor inhibitors
EP1820502A1 (en) * 2006-02-10 2007-08-22 Laboratorios Del Dr. Esteve, S.A. Active substance combination comprising azolylcarbinol compounds
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2292236A1 (en) 2009-08-14 2011-03-09 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention or treatment of pain induced by chemotherapy
EP2335688A1 (en) 2009-11-25 2011-06-22 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical compositions comprising sigma receptor ligands
AR079198A1 (es) 2009-11-25 2012-01-04 Esteve Labor Dr Sales de 4-(2-((5-metil-1-(2-naftalenil) -1h pirazol -3- il)oxi) etil) morfolina
MX339193B (es) 2010-02-04 2016-05-16 Esteve Labor Dr Polimorfos y solvatos de clorhidrato de 4-[2-[[5-metil-1-(2-naftal enil)-1h-pirazol-3-il]oxi]etil]morfolina.
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) * 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460519A1 (en) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2524694A1 (en) * 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)

Also Published As

Publication number Publication date
CN105873580B (zh) 2020-08-25
AU2014364644A1 (en) 2016-06-23
EP3082790A1 (en) 2016-10-26
JP2017503765A (ja) 2017-02-02
IL245977A0 (en) 2016-07-31
KR20160098426A (ko) 2016-08-18
MX2016007286A (es) 2016-08-04
AR101637A1 (es) 2017-01-04
TN2016000229A1 (en) 2017-10-06
US20160310501A1 (en) 2016-10-27
CN105873580A (zh) 2016-08-17
CA2933057A1 (en) 2015-06-25
WO2015091505A1 (en) 2015-06-25
SG11201604478UA (en) 2016-07-28
TW201607539A (zh) 2016-03-01
PH12016501095A1 (en) 2016-07-11

Similar Documents

Publication Publication Date Title
MA39146A1 (fr) Combinaisons de gabapentanoïdes et de ligands des récepteurs sigma
MA38957B1 (fr) Combinaisons d'anti-inflammatoire non stéroïdien (ains) et de ligand des récepteurs sigma
GEP20237506B (en) Pcsk9 antagonist compounds
MA39147B1 (fr) Combinaisons d'inhibiteurs de la recapture de sérotonine-norépinéphrine (snri) et de ligands des récepteurs sigma
EA201591403A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MA39726A (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA39094A1 (fr) Polythérapie comprenant un inhibiteur de mdm2 et un ou plusieurs principes pharmaceutiquement actifs supplémentaires pour le traitement de cancers
EP2868667A4 (en) THERAPEUTIC FOR ANEMIA, INCLUDING NICE ENAMA AND CANCER-INDUCED ANEMIA WITH ANTI-BMP9 ANTIBODY AS ACTIVE AGENT
EA201591404A1 (ru) Спиролактамные модуляторы рецептора nmda и их применение
MA39725B1 (fr) Compositions pharmaceutiques de composés thérapeutiquement actifs
MA47356A1 (fr) Dérivés d'isochromène utiles en tant qu'inhibiteurs des phosphoinositide 3-kinases
MA38810B1 (fr) Inhibiteurs de rorc2 méthodes d'utilisation associées
UA113849C2 (xx) Застосування сигма-лігандів при болю, пов'язаному з діабетом 2 типу
EA201792591A1 (ru) Фармацевтические препараты
UA108859C2 (uk) Ліганди сигма-рецепторів для попередження або лікування болю, викликаного хіміотерапією таксанами, вінкаалкалоїдами, лікарськими засобами на основі платини і талідомідом
MA38253B1 (fr) Compositions comprenant de la vortioxétine et du donépézil
EA201990425A1 (ru) Спиролактамовые и бис-спиролактамовые модуляторы nmda-рецептора и их применение
EA201990428A1 (ru) Спиролактамовые модуляторы nmda-рецептора и их применение
EA201791432A1 (ru) Композиции на основе пролекарства монометилфумарата
PH12015502282A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
EA201791219A1 (ru) Антибактериальные композиции, имеющие широкий спектр активности
MX344846B (es) Combinacion de granulos cargados activos con activos adicionales.
MA42301B1 (fr) Sel cristallin de fumarate de (s)-[3,4-difluoro-2-(2-fluoro-4-iodophénylamino)phényl][3-hydroxy-3-(pipéridin-2-yl)azétidin-1-yl]-méthanone
MA39447B1 (fr) Pirlindole ou ses sels pharmaceutiquement acceptables pour une utilisation en médecine
EP2889039A4 (en) PREPARATION FOR PREVENTING OR TREATING TYPE-1 DIABETES